Filippo Gallina

🧬 Circulating tumor DNA is associated with disease recurrence in those with early stage NSCLC. Here, Feng et al. demonstrate the clinical feasibility of using plasma ctDNA to inform treatment decisions for those with stage I NSCLC. Read more: bit.ly/4xqxN9q

🫁 Stage I LUAD Risk Score. A simple pathology-based score using 4 high-risk histopathologic features (Grade 3, STAS, VPI, LVI) effectively stratified recurrence risk after R0 resection of stage I invasive non-mucinous LUAD. 5-year DFS: • Low risk: 96.5-98.6% • Intermediate risk: 90.9-91.8% • High risk: 71.7-79.3% A practical tool to guide surveillance and adjuvant therapy discussions. 📖 Lung Cancer DOI 👉🏻 doi.org/10.1016/j.lung… #CánCare #NSCLC #lcsm #thoraciconcology #lungadenocarcinoma

🔥Prognostic impact of molecular alterations in resected lung adeno & implications for TNM 10th edition 🆙 @JTOonline ☑EGFR, TP53, KRAS & ALK 🎯TP53/KRAS: potential potential in stage I 🎯ALK: downstaging potential in stages III–IV 🎙Dr. Huatao Tang #LCSM @OncoAlert @Larvol @EGFRResisters @ALKPositiveinc @KRASKickers jto.org/article/S1556-…

New paper in press in @annalsthorsurg . Check out this reconstructed IPD, specifically on stage II NSCLC lead by Dr. Tajè. Thanks to @MThoracics and @DoctorJSpicer for mentoring us and support! annalsthoracicsurgery.org/article/S0003-…

‼️ Landmark #lungcancer research published today in Cell Scientists at the Francis Crick Institute and UCL have discovered a 14-protein blood signature that predicts lung cancer more than 5 years before diagnosis, works in never-smokers, and could identify who benefits from prevention treatment. People with high levels of these proteins were the ones who actually benefited from a drug to damp that inflammation down, cutting their lung cancer risk nearly in half. This could finally give us something lung cancer has never had: a way to prevent it in the people most at risk. doi.org/10.1016/j.cell… #LCSM

𝐀𝐆𝐎 Per sempre. #ASRoma

Happy to share our systematic review & meta-analysis on PD-(L)1 rechallenge strategies in advanced #NSCLC, now out in Cancer Treatment Reviews👇 -->An underserved and still controversial space after prior immunotherapy progression. Hopefully this work helps bring more clarity and supports future development in this challenging setting. Huge thanks to all co-authors for this great international collaboration @stephanieplsaw @Alfdoc2 @gbanna74 @APassaroMD @ReckampK @g_mountzios @FCitarellaMD @Brunet3Leon @valentsant @thenasheffect @RobertoFerrara_ @MassimoDiMaio75 @AminNassarMD @BRicciutiMD @waraonc23 @FabianAckerMD sciencedirect.com/science/articl… @CampusBioMedico @PoliclinCampus @ImperialSandC @IASLC

Engaging discourse in the early stage immunotherapy session at #RomeLung26 touching on MRD, maintenance after pCR (no consensus), limitations of existing datasets, potential role of radiation.

Online here: nature.com/articles/s4158… Open access here: rdcu.be/ff6YJ Key supporters of this work are @CR_UK , @CRUKLungCentre , @UCLHresearch alongside many others

Excited to share our ‘Evolutionary characterization of #LungCancer metastasis’ in #TRACERx & #PEACE, published today in @Nature: a decade spanning effort led by the Jamal-Hanjani lab, @SwantonLab, @NickyMcGranahan & @ZaccaSimo at @uclcancer & @TheCrick. Link below

🫁⚡ Chemoimmunotherapy changed resectable NSCLC. Now surgery is being forced to evolve with it. The oncologic gains are clear. But what happens when patients finally reach the operating room? 🔍 A new systematic review and meta-analysis looking at 27 prospective trials and 2,691 patients shows that surgery after neoadjuvant or perioperative ICI-based therapy remains feasible and generally safe, but it is no longer business as usual. 🏥 Key findings included: 🔹 3% intraoperative complications 🔹 27% postoperative complications 🔹 1% postoperative mortality 🔹 47% minimally invasive surgery use 🔹 20% conversion rate 🔹 10% pneumonectomy rate 🔹 9% surgical delays 💡 The real message is not that surgery becomes impossible. It is that surgery becomes different. Fibrosis, inflammation, altered tissue planes, and regimen-specific risk profiles are changing the operative landscape for thoracic surgeons. That makes multidisciplinary planning, surgical expertise, and treatment centralization more important than ever. 🎯👨‍⚕️👩‍⚕️ In the immunotherapy era, better systemic therapy is not the end of the story. It is the start of a new surgical one. 🚨 oncodaily.com/oncolibrary/lu… @Pietrobiella @filippog92 @DiFedericoMD @oncoblogger @AntonioNuccio01 @giusvisc #NSCLC #LungCancer #ThoracicSurgery #Immunotherapy #Chemoimmunotherapy #ResectableNSCLC #ThoracicOncology #SurgicalOncology #OncoDailyLung #OncoDaily

Dr. Tina Cascone at #AACR26 with a fantastic, data-rich update on genomic markers and ctDNA dynamics from CheckMate 77T. Already an approved SOC after demonstrating increase in pCR and EFS with addition of perioperative nivolumab to neoadjuvant chemo for resectable NSCLC.

Bersani su Costituzione e la destra che vuole cambiarla "inutile volersi far costituenti...non ce la fanno...l'Italia non l'accetta perché sente la Costituzione davanti da raggiungere e non alle spalle...s'inchinassero a lei" Pierluigi sei un grande #Bersani #ottoemezzo #25marzo

New great collaboration with the @NisticoLab!

Fitness is no longer just physiology. The new @thoracic/@EuroRespSoc ERS/ESTS guidelines on fitness for curative intent #LC treatment place patient values, PROs and #MDT discussion at the heart of treatment decisions Worked with @finn_corinne and Pinar Aki to define how QoL and PROs must be assessed pre&post-treatment: they help define fitness and bring patient values into decision-making #LCSM #LungCancer publications.ersnet.org/content/erj/66…

Minimal Residual Disease Enhances Prognostic Stratification Beyond Pathological Response in Resectable Non-Small Cell Lung Cancer aacrjournals.org/clincancerres/… Working together as a team: 3 weeks 3 papers

One of the best translational analyses of a phase 3 peri-operative trial in resectable lung cancer that I've yet seen. Lots of great and very useful data in this extensive manuscript: nature.com/articles/s4301…

Os bombardeios em território venezuelano e a captura do seu presidente ultrapassam uma linha inaceitável. Esses atos representam uma afronta gravíssima à soberania da Venezuela e mais um precedente extremamente perigoso para toda a comunidade internacional. Atacar países, em flagrante violação do direito internacional, é o primeiro passo para um mundo de violência, caos e instabilidade, onde a lei do mais forte prevalece sobre o multilateralismo. A condenação ao uso da força é consistente com a posição que o Brasil sempre tem adotado em situações recentes em outros países e regiões. A ação lembra os piores momentos da interferência na política da América Latina e do Caribe e ameaça a preservação da região como zona de paz. A comunidade internacional, por meio da Organização das Nações Unidas, precisa responder de forma vigorosa a esse episódio. O Brasil condena essas ações e segue à disposição para promover a via do diálogo e da cooperação.

La peste dell’umanità.